Candriam S.C.A. Relay Therapeutics, Inc. Transaction History
Candriam S.C.A.
- $15.6 Billion
- Q1 2025
A detailed history of Candriam S.C.A. transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 580,136 shares of RLAY stock, worth $2.21 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
580,136
Previous 1,729,199
66.45%
Holding current value
$2.21 Million
Previous $7.12 Million
78.68%
% of portfolio
0.01%
Previous 0.04%
Shares
14 transactions
Others Institutions Holding RLAY
# of Institutions
219Shares Held
163MCall Options Held
153KPut Options Held
49.2K-
Sb Investment Advisers (Uk) LTD London, X027.9MShares$106 Million0.67% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.1MShares$46.1 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct10.8MShares$41.3 Million0.07% of portfolio
-
Black Rock Inc. New York, NY10.5MShares$40.2 Million0.0% of portfolio
-
Casdin Capital, LLC New York, NY9.1MShares$34.7 Million2.79% of portfolio
About Relay Therapeutics, Inc.
- Ticker RLAY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 120,219,000
- Market Cap $458M
- Description
- Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...